Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of NX-5948 in Healthy Volunteers
NCT06717269Phase 1Completed
- Sponsor
- Nurix Therapeutics
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised trial of bexobrutideg (7 arms), sponsored by Nurix Therapeutics. Primary endpoints: Area under the concentration-time curve from time 0 to last observed non-zero concentration at 9 weeks, Area under the concentration-time curve from time 0 extrapolated to infinity at 9 weeks and 6 more. Started Nov 2024; status: completed.
02
Drugs
bexobrutideg
Beyond the preview
Go deeper on NCT06717269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717269.